September 12, 2025

FDA Considers Ending Routine Advisory Committees on New Drugs

The FDA move to limit advisory committee involvement in drug approvals has prompted debate on the balance between efficiency and transparency.

KFF Health News

September 04, 2025

'No Standard of Care' for GLP-1 Weaning

Without a defined standard of care for tapering GLP-1 medications, physicians must navigate patient management amid insurer restrictions and high discontinuation rates

KFF Health News

August 19, 2025

Bedtime Cyclobenzaprine Relieves Fibromyalgia: Randomized Trial

Researchers found bedtime sublingual cyclobenzaprine reduced pain versus placebo and improved sleep, fatigue, and function with mostly mild oral adverse events.

Conexiant

January 08, 2025

Modified Consent May Aid Psychedelic Trials

Researchers at the University of California, San Francisco propose modifications to informed consent procedures in psychedelic drug trials, aiming to balance scientific rigor and ethical standards.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant

September 23, 2024

Muscle Relaxants: Limited Long-Term Benefit for Pain

Despite doubling of muscle relaxant prescriptions since 2005, new review finds limited evidence for long-term benefit in most chronic pain conditions.

Conexiant

February 11, 2025

Copper, Iron Levels Tied to Fibromyalgia

A Mendelian randomization study of 400,000 individuals revealed elevated copper increases risk while iron shows protective effects against fibromyalgia.

Conexiant

December 16, 2024

Arthritis Drugs Linked to Fracture Risk

Current gabapentinoid use in patients with inflammatory arthritis was associated with a 36% higher odds of fractures compared to remote use, with risks persisting across most dose levels and showing marked impact shortly after drug initiation.

Conexiant